search for




 

Clinical Course of the Benign Prostate Hyplasia Patients during the Intermittent Use of 5-Alpha Reductase Inhibitors
Urogenit Tract Infect 2019 Dec;14(3):93-8
Published online December 31, 2019;  https://doi.org/10.14777/uti.2019.14.3.93
Copyright © 2019 Korean Association of Urogenital Tract Infection and Inflammation.

Kwibok Choi, Byounghoon Kim, In-Chang Cho, Seung Ki Min

Department of Urology, National Police Hospital, Seoul, Korea
Correspondence to: Seung Ki Min
https://orcid.org/0000-0002-9638-9668
Department of Urology, National Police Hospital, 123 Songi-ro, Songpa-gu, Seoul 05715, Korea
Tel: +82-2-3400-1264, Fax: +82-2-3400-1265
E-mail: drmsk@korea.com
Received November 6, 2019; Revised November 18, 2019; Accepted November 19, 2019.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Purpose: 5-Alpha reductase inhibitors (5ARI), inhibit the conversion of testosterone to dihydrotestosterone, which is essential in prostate hyperplasia, and decreases the prostate volume directly. On the other hand, 5ARI have a range of side effects, such as sexual dysfunction. After the discontinuation of 5ARI, prostate regrowth occurs rapidly until it reaches the baseline size. This study examined the effects of 5ARI when used intermittently.
Materials and Methods: Between March 2009 and May 2017, patients who visited one physician’s outpatient clinic and were diagnosed with BPH underwent transrectal ultrasonography. The selected patients began to take 5ARI until the prostate size decreased at least 10% of the baseline (the first medication). After confirming adequate prostate shrinkage, the patients stopped medication until prostate regrowth reached 50% of the decreased size. After regrowth, they restarted medication for one year (second medication). The prostate size, serum prostate specific antigen (PSA) levels, international prostate symptom score (IPSS) scores, and maximum flow rate (Qmax) in uroflowmetry were collected after the first and second medication and compared using paired t-tests.
Results: Sixty patients with a mean age of 65.1 years were included in the study. The prostate size and serum PSA level increased after the second medication compared to the first, and the prostate reduction and Qmax in uroflowmetry decreased significantly. On the other hand, the symptoms felt by the patients surveyed by the IPSS scores showed no significant difference.
Conclusions: 5ARI appear to be less effective in reducing the prostate volume and improving uroflowmetry after discontinuation.
Keywords : 5-Alpha reductase inhibitors; Prostatic hyperplasia


December 2019, 14 (3)

  • The official journal of

    The Korean Association of Urogenital Tract Infection and Inflammation

    The Korean Continence Society

    The Han-nam Urological Association

    The Korean Society of Geriatric Urological Care